Grifols, S.A. (GIKLY)

USD 5.13

(0.0%)

EBITDA Summary of Grifols, S.A.

  • Grifols, S.A.'s latest annual EBITDA in 2023 was 1.18 Billion EUR , up 6.1% from previous year.
  • Grifols, S.A.'s latest quarterly EBITDA in 2024 Q1 was 347.53 Million EUR , up 3.86% from previous quarter.
  • Grifols, S.A. reported an annual EBITDA of 1.21 Billion EUR in 2022, up 16.4% from previous year.
  • Grifols, S.A. reported an annual EBITDA of 922.27 Million EUR in 2021, down -29.71% from previous year.
  • Grifols, S.A. reported a quarterly EBITDA of 364.51 Million EUR for 2024 Q2, up 4.89% from previous quarter.
  • Grifols, S.A. reported a quarterly EBITDA of 252.84 Million EUR for 2023 Q2, down -10.89% from previous quarter.

Annual EBITDA Chart of Grifols, S.A. (2023 - 2005)

Historical Annual EBITDA of Grifols, S.A. (2023 - 2005)

Year EBITDA EBITDA Growth
2023 1.18 Billion EUR 6.1%
2022 1.21 Billion EUR 16.4%
2021 922.27 Million EUR -29.71%
2020 1.29 Billion EUR -8.78%
2019 1.42 Billion EUR 23.48%
2018 1.22 Billion EUR 0.98%
2017 1.28 Billion EUR 4.61%
2016 1.14 Billion EUR 0.01%
2015 1.16 Billion EUR 11.07%
2014 1.04 Billion EUR 21.86%
2013 864.58 Million EUR 6.86%
2012 776.26 Million EUR 111.56%
2011 341.42 Million EUR 54.66%
2010 233.65 Million EUR -6.12%
2009 255.94 Million EUR 5.48%
2008 243.67 Million EUR 27.77%
2007 190.71 Million EUR 117.48%
2006 100.94 Million EUR 35.77%
2005 75.99 Million EUR 0.0%

Peer EBITDA Comparison of Grifols, S.A.

Name EBITDA EBITDA Difference
AstraZeneca PLC 13.28 Billion USD 91.106%
Bristol-Myers Squibb Company PFD CONV 2 19.41 Billion USD 93.913%
CSPC Pharmaceutical Group Limited 1.14 Billion USD -2.955%
Clarus Therapeutics Holdings, Inc. -39.7 Million USD 3076.945%
Novartis AG 19.51 Billion USD 93.944%
PT Kalbe Farma Tbk. 288.13 Million USD -310.225%